Cardiogen vs PEG-MGF
Side-by-side comparison of key properties, dosing, and research.
- Summary
- Cardiogen is a tetrapeptide bioregulator (Ala-Glu-Asp-Arg) developed by Professor Vladimir Khavinson. It is a tissue-specific bioregulator for the heart and myocardium, designed to normalize cardiomyocyte function and support cardiac tissue regeneration. Research has demonstrated cardioprotective effects, improved cardiac rhythm, and benefits in recovery from ischemic injury.
- PEG-MGF (Pegylated Mechano Growth Factor) is a modified form of MGF (Mechano Growth Factor) where polyethylene glycol (PEG) chains have been attached to extend its half-life from minutes to days. Native MGF is released locally in muscle in response to mechanical stress and quickly degrades. PEGylation allows systemic administration with sustained circulation, enabling whole-body muscle repair and anabolic signaling rather than the purely local effect of native MGF.
- Half-Life
- Short (minutes); gene-regulatory effects persist longer
- ~3 days (due to PEGylation)
- Admin Route
- SubQ, Oral
- SubQ
- Research
- —
- —
- Typical Dose
- 10 mg per day
- 200–400 mcg
- Frequency
- Daily for 10–30 days
- 2–3x per week
- Key Benefits
- Cardioprotective effects on myocardial tissue
- Normalization of cardiomyocyte protein synthesis
- May improve cardiac rhythm and conduction
- Support for recovery from ischemic cardiac events
- Anti-aging effects on heart tissue
- Potential reduction in cardiac fibrosis
- Often combined with Epithalon for comprehensive cardiovascular longevity support
- Extended half-life (~3 days) vs native MGF (minutes)
- Systemic muscle satellite cell activation via subcutaneous injection
- Promotes muscle fiber repair and hypertrophy throughout the body
- Enhanced recovery from intense training or muscle injury
- Synergistic with IGF-1 LR3 and growth hormone peptides
- Useful in sarcopenia, post-injury recovery, and athletic performance
- Single injection provides multi-day anabolic signaling
- Side Effects
- Generally well tolerated in available research
- Mild injection site reactions
- No significant adverse cardiovascular events reported at standard doses
- Water retention and localized swelling
- Potential hypoglycemia at high doses
- Theoretical cancer growth risk (growth factor)
- Injection site reactions
- +1 more
- Stacks With
- —
- —